[{"id":"5e4173a0-f1b6-45fa-9023-3e3fc9e7ede2","acronym":"YAPPETIZER","url":"https://clinicaltrials.gov/study/NCT03358017","created_at":"2021-01-18T16:34:31.703Z","updated_at":"2024-07-02T16:35:32.529Z","phase":"Phase 2","brief_title":"Neoadjuvant Zoledronate and Atorvastatin in Triple Negative Breast Cancer","source_id_and_acronym":"NCT03358017 - YAPPETIZER","lead_sponsor":"Mario Negri Institute for Pharmacological Research","biomarkers":" HER-2 • TP53 • PGR • BRCA • TAFAZZIN","pipe":" | ","alterations":" PGR negative","tags":["HER-2 • TP53 • PGR • BRCA • TAFAZZIN"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e PGR negative"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e zoledronic acid • atorvastatin"],"overall_status":"Completed","enrollment":" Enrollment 54","initiation":"Initiation: 03/05/2018","start_date":" 03/05/2018","primary_txt":" Primary completion: 06/17/2021","primary_completion_date":" 06/17/2021","study_txt":" Completion: 07/25/2023","study_completion_date":" 07/25/2023","last_update_posted":"2023-10-19"},{"id":"d2690b1d-65e0-4c96-b9ca-3b3247994b3e","acronym":"METZOLIMOS","url":"https://clinicaltrials.gov/study/NCT02517918","created_at":"2021-01-18T12:10:03.624Z","updated_at":"2024-07-02T16:35:59.884Z","phase":"Phase 1","brief_title":"Metronomic Chemotherapy in Patients With Advanced Solid Tumor With Bone Metastasis and Advanced Pretreated Osteosarcoma","source_id_and_acronym":"NCT02517918 - METZOLIMOS","lead_sponsor":"Institut Bergonié","biomarkers":" CD8 • CD4 • IL2 • TGFB1","pipe":"","alterations":" ","tags":["CD8 • CD4 • IL2 • TGFB1"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e cyclophosphamide • sirolimus • zoledronic acid • cyclophosphamide intravenous"],"overall_status":"Completed","enrollment":" Enrollment 23","initiation":"Initiation: 02/01/2015","start_date":" 02/01/2015","primary_txt":" Primary completion: 09/05/2016","primary_completion_date":" 09/05/2016","study_txt":" Completion: 11/16/2021","study_completion_date":" 11/16/2021","last_update_posted":"2022-11-29"},{"id":"cc62689a-9210-4497-9d99-6a97e2c2429c","acronym":"","url":"https://clinicaltrials.gov/study/NCT00566618","created_at":"2021-01-18T02:04:00.307Z","updated_at":"2025-02-25T14:25:22.607Z","phase":"Phase 1/2","brief_title":"Dasatinib in Combination With Zoledronic Acid for the Treatment of Breast Cancer With Bone Metastasis","source_id_and_acronym":"NCT00566618","lead_sponsor":"M.D. Anderson Cancer Center","biomarkers":" ER • PGR","pipe":" | ","alterations":" ER positive • PGR positive","tags":["ER • PGR"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e ER positive • PGR positive"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e dasatinib • zoledronic acid"],"overall_status":"Completed","enrollment":" Enrollment 31","initiation":"Initiation: 11/01/2007","start_date":" 11/01/2007","primary_txt":" Primary completion: 11/17/2020","primary_completion_date":" 11/17/2020","study_txt":" Completion: 11/17/2020","study_completion_date":" 11/17/2020","last_update_posted":"2022-02-25"},{"id":"8f50e9b1-ff0c-4afd-a3ec-80122b68a4d6","acronym":"","url":"https://clinicaltrials.gov/study/NCT05164952","created_at":"2021-12-21T15:53:30.757Z","updated_at":"2024-07-02T16:36:19.303Z","phase":"Phase 3","brief_title":"Delayed Versus Immediate Use Of Zoledronic Acid For Postmenopausal Patients With Early Breast Cancer Who Are Using Adjuvant Letrozole","source_id_and_acronym":"NCT05164952","lead_sponsor":"Assiut University","biomarkers":" PGR","pipe":" | ","alterations":" ER positive + PGR positive • PGR positive","tags":["PGR"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e ER positive + PGR positive • PGR positive"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e letrozole • zoledronic acid"],"overall_status":"Recruiting","enrollment":" Enrollment 50","initiation":"Initiation: 09/30/2021","start_date":" 09/30/2021","primary_txt":" Primary completion: 08/30/2023","primary_completion_date":" 08/30/2023","study_txt":" Completion: 09/30/2023","study_completion_date":" 09/30/2023","last_update_posted":"2021-12-21"},{"id":"1351f523-36c8-40f9-bb90-b10356338d46","acronym":"","url":"https://clinicaltrials.gov/study/NCT04045522","created_at":"2021-01-18T19:50:16.442Z","updated_at":"2024-07-02T16:36:27.655Z","phase":"","brief_title":"Study on Bisphosphonates Targeting Triple-negative Breast Cancer","source_id_and_acronym":"NCT04045522","lead_sponsor":"Shengjing Hospital","biomarkers":" HER-2 • ER • PGR","pipe":"","alterations":" ","tags":["HER-2 • ER • PGR"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e zoledronic acid"],"overall_status":"Recruiting","enrollment":" Enrollment 120","initiation":"Initiation: 09/01/2019","start_date":" 09/01/2019","primary_txt":" Primary completion: 08/31/2021","primary_completion_date":" 08/31/2021","study_txt":" Completion: 08/31/2022","study_completion_date":" 08/31/2022","last_update_posted":"2021-07-20"},{"id":"2c13ee0a-6026-4fbc-beb7-3db069f73fe2","acronym":"NEO-ZOTAC","url":"https://clinicaltrials.gov/study/NCT01099436","created_at":"2021-01-18T04:20:55.612Z","updated_at":"2025-02-25T15:50:59.853Z","phase":"Phase 3","brief_title":"Neo-Adjuvant Chemotherapy (TAC) With or Without Zoledronic Acid in Treating HER2-negative Breast Cancer Patients","source_id_and_acronym":"NCT01099436 - NEO-ZOTAC","lead_sponsor":"Borstkanker Onderzoek Groep","biomarkers":" HER-2 • PGR","pipe":" | ","alterations":" HER-2 negative","tags":["HER-2 • PGR"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e HER-2 negative"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e docetaxel • doxorubicin hydrochloride • cyclophosphamide • zoledronic acid"],"overall_status":"Completed","enrollment":" Enrollment 250","initiation":"Initiation: 04/01/2010","start_date":" 04/01/2010","primary_txt":" Primary completion: 04/01/2012","primary_completion_date":" 04/01/2012","study_txt":" Completion: 09/01/2013","study_completion_date":" 09/01/2013","last_update_posted":"2020-01-21"},{"id":"48626291-e00b-4fdb-b9cb-b63fcd4aa449","acronym":"","url":"https://clinicaltrials.gov/study/NCT00436917","created_at":"2021-01-18T01:32:33.333Z","updated_at":"2024-07-02T16:36:55.788Z","phase":"","brief_title":"Zoledronate in Treating Osteopenia or Osteoporosis in Postmenopausal Women Receiving Letrozole for Stage I, Stage II, or Stage IIIA Primary Breast Cancer","source_id_and_acronym":"NCT00436917","lead_sponsor":"Mayo Clinic","biomarkers":" ER • PGR","pipe":" | ","alterations":" PGR positive","tags":["ER • PGR"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e PGR positive"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e letrozole • zoledronic acid"],"overall_status":"Completed","enrollment":" Enrollment 60","initiation":"Initiation: 04/01/2006","start_date":" 04/01/2006","primary_txt":" Primary completion: 06/01/2008","primary_completion_date":" 06/01/2008","study_txt":" Completion: 05/09/2016","study_completion_date":" 05/09/2016","last_update_posted":"2019-09-11"},{"id":"7a73dccc-9d32-4819-ad4d-1d2be356e9d4","acronym":"","url":"https://clinicaltrials.gov/study/NCT01194440","created_at":"2021-01-18T04:46:49.510Z","updated_at":"2024-07-02T16:37:06.996Z","phase":"Phase 2","brief_title":"Zoledronic Acid in Aromatase Inhibitor Induced Musculoskeletal Symptoms","source_id_and_acronym":"NCT01194440","lead_sponsor":"Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins","biomarkers":" PGR","pipe":" | ","alterations":" PGR positive","tags":["PGR"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e PGR positive"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e letrozole • zoledronic acid"],"overall_status":"Completed","enrollment":" Enrollment 63","initiation":"Initiation: 02/01/2011","start_date":" 02/01/2011","primary_txt":" Primary completion: 01/01/2014","primary_completion_date":" 01/01/2014","study_txt":" Completion: 01/01/2014","study_completion_date":" 01/01/2014","last_update_posted":"2018-09-12"},{"id":"0e1a0476-b51c-4968-8ca9-c6ddc11af645","acronym":"NSABP-B-34","url":"https://clinicaltrials.gov/study/NCT00009945","created_at":"2021-01-17T23:54:53.121Z","updated_at":"2024-07-02T16:37:15.538Z","phase":"Phase 3","brief_title":"Clodronate With or Without Chemotherapy and/or Hormonal Therapy in Treating Women With Stage I or Stage II Breast Cancer","source_id_and_acronym":"NCT00009945 - NSABP-B-34","lead_sponsor":"NSABP Foundation Inc","biomarkers":" PGR","pipe":"","alterations":" ","tags":["PGR"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e clodronate disodium"],"overall_status":"Completed","enrollment":" Enrollment 3323","initiation":"Initiation: 01/01/2001","start_date":" 01/01/2001","primary_txt":" Primary completion: 03/01/2011","primary_completion_date":" 03/01/2011","study_txt":" Completion: 12/01/2012","study_completion_date":" 12/01/2012","last_update_posted":"2017-12-13"},{"id":"0e0af965-9019-4216-8632-a165e17947c6","acronym":"","url":"https://clinicaltrials.gov/study/NCT01204203","created_at":"2021-01-18T04:49:32.600Z","updated_at":"2025-02-25T15:51:21.743Z","phase":"Phase 2","brief_title":"Pilot Study of Bisphosphonate Therapy (Zoledronic Acid) in Patients With Malignant Mesothelioma (UAB 0901)","source_id_and_acronym":"NCT01204203","lead_sponsor":"University of Alabama at Birmingham","biomarkers":" ALK","pipe":"","alterations":" ","tags":["ALK"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e zoledronic acid"],"overall_status":"Completed","enrollment":" Enrollment 8","initiation":"Initiation: 06/01/2009","start_date":" 06/01/2009","primary_txt":" Primary completion: 04/01/2015","primary_completion_date":" 04/01/2015","study_txt":" Completion: 04/01/2016","study_completion_date":" 04/01/2016","last_update_posted":"2017-05-24"},{"id":"4e2b0caf-43a6-4ba6-a703-c57392fe8679","acronym":"","url":"https://clinicaltrials.gov/study/NCT00107263","created_at":"2021-01-18T00:20:58.936Z","updated_at":"2024-07-02T16:37:27.247Z","phase":"Phase 3","brief_title":"Zoledronate in Preventing Bone Loss in Postmenopausal Women Who Are Receiving Letrozole for Stage I, Stage II, or Stage IIIA Breast Cancer","source_id_and_acronym":"NCT00107263","lead_sponsor":"Alliance for Clinical Trials in Oncology","biomarkers":" ER • PGR","pipe":" | ","alterations":" PGR positive","tags":["ER • PGR"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e PGR positive"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e tamoxifen • letrozole • zoledronic acid"],"overall_status":"Completed","enrollment":" Enrollment 558","initiation":"Initiation: 01/01/2005","start_date":" 01/01/2005","primary_txt":" Primary completion: 03/01/2007","primary_completion_date":" 03/01/2007","study_txt":" Completion: 08/01/2012","study_completion_date":" 08/01/2012","last_update_posted":"2016-12-06"},{"id":"c77a0d3c-0887-4698-a978-af2e3499624a","acronym":"","url":"https://clinicaltrials.gov/study/NCT00692458","created_at":"2021-01-18T02:35:17.464Z","updated_at":"2024-07-02T16:37:29.839Z","phase":"Phase 3","brief_title":"A Study to Assess the Effects of MK0822 in Reducing the Risk of Bone Metastasis in Women With Breast Cancer (0822-029)","source_id_and_acronym":"NCT00692458","lead_sponsor":"Merck Sharp \u0026 Dohme LLC","biomarkers":" HER-2","pipe":" | ","alterations":" HER-2 positive","tags":["HER-2"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e HER-2 positive"],"overall_status":"Withdrawn","enrollment":"","initiation":"Initiation: 09/01/2008","start_date":" 09/01/2008","primary_txt":" Primary completion: 09/01/2008","primary_completion_date":" 09/01/2008","study_txt":" Completion: 09/01/2008","study_completion_date":" 09/01/2008","last_update_posted":"2016-08-12"}]